MorphoSys : Reports First Quarter 2021 Results

Media Release

Planegg/Munich, Germany, May 5, 2021

MorphoSys AG Reports First Quarter 2021 Results

• • Monjuvi U.S. net product sales of € 12.9 million (US$ 15.5 million)
  • • • Tremfya royalties of € 11.6 million
    • Reaffirming group revenue guidance of € 150 to € 200 million
• Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST (1:00pm BST/8:00am EDT)

MorphoSys AG (FSE:MOR; NASDAQ:MOR) reports financial results for the first quarter of 2021.

"For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. "While we experienced headwinds from the pandemic in the first quarter, we are cautiously optimistic that the COVID-19 impact in the U.S. will start to diminish in the second half of 2021. We are confident in the potential of Monjuvi given its broad second-line label and overall profile in the r/r DLBCL setting. We are also making important progress initiating key trials for both tafasitamab and felzartamab this year."

Tafasitamab Highlights

• Monjuvi® (tafasitamab-cxix) U.S. net product sales of € 12.9 million (US$ 15.5 million).
• Monjuvi was granted a product-specific HCPCS J-Code, effective April 1, 2021.
• On January 5, 2021, MorphoSys and Incyte announced that the Swiss Agency for Therapeutic Products (Swissmedic) had accepted the marketing authorization application (MAA) for tafasitamab and on January 12, 2021, MorphoSys and Incyte announced that Health Canada had accepted the New Drug Submission (NDS) for tafasitamab. Both applications seek approval for tafasitamab, in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplantation (ASCT).

Pipeline Highlights

Felzartamab:

• M-PLACEstudy of felzartamab in autoimmune membranous nephropathy ongoing: the safety run-in phase was completed and the full enrollment phase opened.
• In February 2021, the first patient with autoimmune membranous nephropathy was dosed with felzartamab in the New-PLACE study, a phase 2 study evaluating different treatment schedules to identify the regimen for the pivotal study.

Page 1 of 7

Otilimab:

• On March 2, 2021, we announced that our partner GSK reported preliminary results of the OSCAR study using otilimab for the treatment of severe pulmonary COVID-19 related disease. Given these data suggest an important clinical benefit in a pre-definedsub-group of high-risk patients and the urgent public health need, GSK has amended the OSCAR study to expand this cohort to confirm these potentially significant findings. The dosing of the first patient in the expanded study triggered milestone payments totaling € 16 million to MorphoSys.

MOR210:

• On January 25, 2021, MorphoSys and I-Mab announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MOR210/TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the United States.

Corporate Updates

• On January 6, 2021, MorphoSys announced the appointment of Sung Lee as Chief Financial Officer, effective as of February 2, 2021.

Significant Events After The Reporting Period

• On April 19, 2021, MorphoSys and Incyte announced that the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Page 2 of 7

First Quarter 2021 Financial Results (IFRS)

Total revenues for the quarter ended March 31, 2021 were € 47.2 million compared to

• 251.2 million for the comparable period in 2020. The year-over-year decline was driven by the upfront payment of the collaboration and license agreement with Incyte in the first quarter 2020 for the out-licensing of tafasitamab outside the USA.

in € million		3M 2021		3M 2020		Change
Total revenues	47.2		251.2	(81%)
Monjuvi product sales	12.9		-	-
Royalties	11.6		9.3	25%
Licenses, milestones and other	22.7		241.9	(91%)

Cost of Sales: In the first three months of 2021, cost of sales increased to € 5.0 million (3M

2020: € 3.3 million).

Research and Development (R&D) Expenses: In the first three months of 2021, research

and development expenses were € 33.3 million (3M 2020: € 21.5 million). Growth over 2020 reflects the increased investment to support the advancement of proprietary programs and consisted primarily of expenses for external laboratory services and personnel expenses.

Selling, General and Administrative (SG&A) Expenses: Selling expenses increased in the

first three months of 2021 to € 28.2 million (3M 2020: € 12.8 million) and general and

administrative expenses remained almost unchanged at € 10.3 million (3M 2020:€ 10.1 million). The year-over-year increase in selling expenses was primarily driven by the full quarter impact of the expenses for services provided by Incyte as part of the joint U.S. marketing activities for Monjuvi.

Operating Loss: Operating loss amounted to € 29.6 million in the first three months of 2021

(3M 2020: operating profit of € 203.5 million).

Consolidated Net Loss: For the first three months of 2021, consolidated net loss was € 41.6

million (3M 2020: consolidated net profit of € 195.5 million).

Cash and Investments: As of March 31, 2021, the Company had cash and investments of

• 1,215.0 million compared to € 1,244.0 million on December 31, 2020.

Number of shares: The number of shares issued remained unchanged since year-end 2020 and totaled 32,890,046.

Page 3 of 7

Financial Guidance and Operational Outlook for 2021

in € million

Group Revenues

Operating Expenses

R&D expense as a % of Operating Expenses

Financial Guidance 2021

150 to 200*

355 to 385**

45 to 50%

*Group revenues includes the announced € 16 million milestone payments from GSK, but excludes other potential significant milestones from development partners and/or licensing partnerships. This revenue guidance is subject to a number of uncertainties including the potential for variability from the first full year of the Monjuvi product launch, the limited visibility that MorphoSys has on the Tremfya royalty stream as well as the ongoing COVID-19 pandemic and the impact on our as well as our partner's business operations.

**Operating expenses is comprised of R&D and SG&A, inclusive of Incyte's share of Monjuvi selling costs in the USA.

MorphoSys expects for Tafasitamab the following events and activities in 2021:

• Continuation of the phase 1b trial with tafasitamab in previously untreated DLBCL (firstMIND);
• Initiation of a pivotal phase 3 trial of tafasitamab in previously untreated DLBCL (frontMIND);
• Continuation of the phase 3 inMIND trial of tafasitamab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL);
• Investigation of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory DLBCL, first-line DLBCL and relapsed or refractory follicular lymphoma (r/r FL) jointly with Incyte and Xencor;
• Continuation of the L-MIND study of tafasitamab and evaluate the long-term efficacy and safety data;
• Continuation of the phase 3 B-MIND study of tafasitamab in combination with bendamustine for r/r DLBCL;
• Presentation of data from the 3-year follow up of L-MIND as well as other abstracts at several scientific conferences (e.g. ASCO, EHA);
• Decision on the European Marketing Authorization Application (MAA), seeking approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with r/r DLBCL which is currently under review;
• Support of Incyte in submitting marketing authorization applications in other markets.

Page 4 of 7

MorphoSys Group Key Figures (IFRS, March 31, 2021)

in € million		3M 2021		3M 2020		Change
Revenues	47.2	251.2	(81%)
Monjuvi product sales	12.9	-	-
Royalties	11.6	9.3	25%
Licenses, milestones and other	22.7	242.0	(91%)
Cost of Sales	(5.0)	(3.3)	52%
Gross Profit	42.1	248.0	(83%)
Total Operating Expenses:	(71.7)	(44.4)	61%
Research and Developlment	(33.3)	(21.5)	55%
Selling	(28.2)	(12.8)	> 100%
General and Administrative	(10.3)	(10.1)	(2%)
Operating Profit / (Loss)	(29.6)	203.5	> (100%)
Consolidated Net Profit (+) / (Loss)	(41.6)	195.5	> (100%)
Earnings per Share, Basic and Diluted (in €)	(1.27)
Earnings per Share, Basic (in €)	-	6.12	-
Earnings per Share, diluted (in €)	-	6.11	-
Cash and investments (end of period)	1,215.0	1,244.0*	(2%)

*Value as of December 31, 2020

MorphoSys will hold its conference call and webcast tomorrow, May 6, 2021, to present the results for the first quarter of 2021 and the further outlook for 2021.

Dial-in number for the conference call (in English) at 2:00pm CEST; 1:00pm BST; 8:00am EDT:

Germany:	+49	69 201 744 220
For UK residents:	+44	203 009 2470
For US residents:	[phone]
(all numbers reachable from any geography)
Participant PIN:	30606690#

Please dial in 10 minutes before the beginning of the conference.

A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website at http://www.morphosys.comand after the call, a slide- synchronized audio replay of the conference will be available at the same location.

The interim statement for the first quarter of 2021 (IFRS) is available online: http://www.morphosys.com/Reports

Page 5 of 7